2%聚多卡醇机械化学消融治疗小隐静脉功能不全的早期结果
本研究为单中心回顾性分析60例接受机械化学消融(MOCA)治疗单轴小隐静脉功能不全的患者,使用ClariVein导管联合2%聚多卡醇,必要时加做微创静脉切除术。技术成功率100%,术后第1天视觉模拟评分平均15 mm,无严重不良事件。1、6、12个月闭塞率分别为100%、98.3%、92.6%,静脉临床严重程度评分和生活质量均显著改善。
要点
- MOCA治疗小隐静脉功能不全技术成功率100%,12个月闭塞率92.6%。
- 无腓肠神经损伤或深静脉血栓等严重并发症,术后疼痛轻微。
- 静脉临床严重程度评分和Aberdeen静脉曲张问卷评分在随访中显著改善。
核心结论
- MOCA是治疗小隐静脉功能不全可行、安全且疼痛轻微的方法,12个月闭塞率达92.6%。
- 未观察到腓肠神经损伤或其他严重并发症,并取得良好的临床效果和患者生活质量改善。
研究设计与样本
- 单中心、回顾性分析前瞻性收集的数据库,纳入60例接受MOCA治疗的单轴小隐静脉功能不全患者。
- 所有手术在局部麻醉下使用ClariVein导管联合2%聚多卡醇,必要时附加微创静脉切除术。
主要发现
- 技术成功率为100%(60/60)。
- 术后第1天视觉模拟评分平均为15 mm。
- 1、6、12个月随访的闭塞率分别为100%(60/60)、98.3%(57/58)、92.6%(50/54)。
- 静脉临床严重程度评分中位数从基线5(IQR 3-6)降至1个月2(IQR 1-4)、6个月1(IQR 1-2)、12个月1(IQR 0-1),均P < .001。
- Aberdeen静脉曲张问卷平均分从基线25 ± 14.61改善至1个月15.81 ± 13.76、6个月9.81 ± 7.42、12个月4.73 ± 3.32,均P < .001。
关键数值与推荐
- 轻微并发症包括瘀斑3.3%(2/60)、小隐静脉一过性血栓性静脉炎5%(3/60)、瘙痒3.3%(2/60)。
- 未记录严重不良事件,未观察到神经并发症或深静脉血栓。
临床怎么用
- 对于小隐静脉功能不全,可考虑采用ClariVein导管联合2%聚多卡醇的MOCA作为局部麻醉下的治疗选择。
- 术后应随访评估闭塞率、静脉临床严重程度评分和生活质量改善情况。
局限性
- 单中心回顾性分析,样本量60例,随访至12个月,早期结果需更长期和大样本研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of the present study was to investigate the early results of mechanochemical ablation (MOCA) for the treatment of small saphenous vein (SSV) incompetence. METHODS: We performed a single-center, retrospective analysis of a prospectively collected database of 60 patients treated with MOCA for single-axis SSV incompetence. All procedures were performed with the patient under local anesthesia using the ClariVein catheter (Merit Medical, South Jordan, Utah) combined with 2% polidocanol and, where appropriate, additional microphlebectomy. The primary study endpoint was to assess the SSV occlusion rate at the 1-, 6-, and 12-month follow-up examinations. The secondary endpoints included the Venous Clinical Severity Score, quality of life (QoL) assessment, periprocedural pain, and further complications after the intervention and during the follow-up period. Patient QoL was assessed using the Aberdeen Varicose Vein Questionnaire. Pain was measured using a 100-mm visual analog scale. RESULTS: Technical success was achieved in 100% of the cases. The mean visual analog scale score on the first postoperative day was 15 mm. No major events were recorded. No neurological complications or deep vein thrombosis were observed. Minor complications included ecchymosis in 3.3% of cases (2 of 60), transient phlebitis of the SSV in 5% of cases (3 of 60), and itching in 3.3% of cases (2 of 60). At the 1-, 6-, and 12-month follow-up examinations, the occlusion rate was 100% (60 of 60), 98.3% (57 of 58), and 92.6% (50 of 54). The median Venous Clinical Severity Score had significantly decreased from 5 (interquartile range [IQR], 3-6) at baseline to 2 (IQR, 1-4) at the 1-month follow-up (P < .001), 1 (IQR, 1-2) at the 6-month follow-up (P < .001) and 1 (IQR, 0-1) at the 12-month follow-up (P < .001). The mean Aberdeen Varicose Vein Questionnaire score had improved from the baseline score of 25 ± 14.61 to 15.81 ± 13.76 at the 1-month follow-up (P < .001), to 9.81 ± 7.42 at the 6-month follow-up (P < .001) and 4.73 ± 3.32 at the 12-month follow-up (P < .001). CONCLUSIONS: The results of our study have shown that MOCA is a feasible, safe, and painless procedure for the treatment of SSV incompetence with an occlusion rate of 92.6% at the 12-month examination. No sural nerve injuries or other major complications were observed. The procedure also provided good clinical results and positive effects on patient QoL.
引用
- Baccellieri D, Apruzzi L, Ardita V, et al. Early results of mechanochemical ablation for small saphenous vein incompetency using 2% polidocanol. J Vasc Surg Venous Lymphat Disord. 2020. PMID: 32916372. doi:10.1016/j.jvsv.2020.09.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。